REVIEW ARTICLE

You have free access to this content

Koebner’s phenomenon in vitiligo: European position paper

  1. Nanja van Geel1,
  2. Reinhart Speeckaert1,
  3. Alain Taieb2,
  4. Mauro Picardo3,
  5. Markus Böhm4,
  6. David J. Gawkrodger5,
  7. Karin Schallreuter6,
  8. Dorothy C. Bennett7,
  9. Wietze van der Veen8,
  10. Maxine Whitton9,
  11. Silvia Moretti10,
  12. Wiete Westerhof11,
  13. Khaled Ezzedine2,
  14. Yvon Gauthier2,
  15. on behalf of the other VETF members†

Article first published online: 7 MAR 2011

DOI: 10.1111/j.1755-148X.2011.00838.x

Issue

Pigment Cell & Melanoma Research

Pigment Cell & Melanoma Research

Volume 24, Issue 3, pages 564–573, June 2011

Additional Information

How to Cite

van Geel, N., Speeckaert, R., Taieb, A., Picardo, M., Böhm, M., Gawkrodger, D. J., Schallreuter, K., Bennett, D. C., van der Veen, W., Whitton, M., Moretti, S., Westerhof, W., Ezzedine, K., Gauthier, Y. and on behalf of the other VETF members (2011), Koebner’s phenomenon in vitiligo: European position paper. Pigment Cell & Melanoma Research, 24: 564–573. doi: 10.1111/j.1755-148X.2011.00838.x

Author Information

  1. 1

     Department of Dermatology, Ghent University Hospital, Ghent, Belgium

  2. 2

     Service de Dermatologie, CHU de Bordeaux, Bordeaux cédex, France

  3. 3

     San Gallicano Dermatology Institute, Via Elio Chianesi, Roma, Italy

  4. 4

     Department of Dermatology, University of Münster; Münster, Germany

  5. 5

     Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK

  6. 6

     Centre of Skin Sciences, School of Life Sciences, University of Bradford, UK and Institute for Pigmentary Disorders in association with EM Arndt University of Greifswald, Greifswald, Germany

  7. 7

     Centre for Molecular & Metabolic Signalling, Division of Basic Medical Sciences, St. George’s, University of London, Cranmer Terrace, London, UK

  8. 8

     Department of Dermatology, AMC/University of Amsterdam, Netherlands Institute for Pigment Disorders, Amsterdam, the Netherlands

  9. 9

     The Cochrane Skin Group, Centre for Evidence Base Dermatology, University of Nottingham, Nottingham, UK

  10. 10

     Division of Clinical, Preventive and Oncologic Dermatology, University of Florence, Florence, Italy

  11. 11

     Color Foundation, Landsmeer, the Netherlands

  1. †

    A. Alomar (Barcelona), L. Benzekri (Rabat), Dell’Anna (Rome), A. de Pase (Bergamo), V. Eleftheriadou (Nottingham), T. Jouary (Bordeaux), G. Leone (Rome), L. Nieuweboer-Krobotova (Amsterdam), A. Wolkerstorfer (Amsterdam), M.J. Olsson (Uppsala), T. Passeron (Nice), J.P. Ortonne (Nice), A. Tanew (Vienna).

*Nanja van Geel, e-mail: Nanja.vangeel@UGent.be; Yvon Gauthier, e-mail: yvongauthier@free.fr

  1. †

    A. Alomar (Barcelona), L. Benzekri (Rabat), Dell’Anna (Rome), A. de Pase (Bergamo), V. Eleftheriadou (Nottingham), T. Jouary (Bordeaux), G. Leone (Rome), L. Nieuweboer-Krobotova (Amsterdam), A. Wolkerstorfer (Amsterdam), M.J. Olsson (Uppsala), T. Passeron (Nice), J.P. Ortonne (Nice), A. Tanew (Vienna).

Publication History

  1. Issue published online: 16 MAY 2011
  2. Article first published online: 7 MAR 2011
  3. Accepted manuscript online: 16 FEB 2011 10:08PM EST
  4. PUBLICATION DATA Received 9 December 2010, revised and accepted for publication 14 February 2011, published online 16 February 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (400K)

Keywords:

  • Koebner’s phenomenon;
  • isomorphic response;
  • vitiligo;
  • melanocytorrhagy;
  • review;
  • pathogenesis;
  • trauma

Summary

Koebner’s phenomenon (KP) has been observed in a number of skin diseases, including vitiligo. Its clinical significance in vitiligo with respect to disease activity and course is still debatable, while its relevance for surgical techniques has been demonstrated in some reports. We present a literature review on the currently known facts about KP in vitiligo, including details of clinical, experimental, and histopathological changes. The consensus view is that there are still no methods to define and assess KP in vitiligo. A new classification is proposed to allow an evaluation of KP in daily practice or in experimental studies. However, many unanswered questions still remain after redefining KP in patients with vitiligo. Active research focusing on KP in vitiligo may not only provide unexpected clues in the pathogenesis of vitiligo but also help to tailor novel therapies against this chronic and often psychologically devastating skin disease.

View Full Article with Supporting Information (HTML) Get PDF (400K)